List of other intravenous thrombolytic drugs
| Agent | Mechanism | Trial | Implication | Results |
| Urokinase (UK) | Directly act on fibrinogen | UK37 | UK 1.5 million IU group (n=155), UK 1 million IU group (n=162, placebo group (n=148) | Thrombolysis was safe and effective |
| Tenecteplase | More specific binding of fibrinogen to plasminogen into plasmin | ATTEST145 | Tenecteplase and tPA group (n=52, respectively) | Onset within 4.5 hour in patients with AIS treated with tenecteplase and alteplase had similar neurological and imaging outcome |
| TEMPO-1146 | Tenecteplase (0.1 mg/kg and 0.25 mg/kg group (n=25 respectively) | Onset within 12 hours in patients with mild AIS (NIHSS ≤5 min) with intracranial artery occlusion. Better outcome in 0.25 mg/kg group. | ||
| Desmoteplase | Very strong fibrinolytic activity | DIAS-3147 | Desmoteplase group (n=247), placebo group (n=245) | Onset within 3–9 hours in patients with AIS with cerebral artery occlusion or high-grade stenosis No better outcome in desmoteplase group but less safety issue. |
ATTEST, Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis; DIAS, Desmoteplase in Acute Ischemic Stroke; NIHSS, National Institution of Health Stroke Scale; TEMPO, TNK–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke with Proven Occlusion; UK, urokinase.